| pubmed-article:9863011 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:9863011 | lifeskim:mentions | umls-concept:C0033325 | lld:lifeskim |
| pubmed-article:9863011 | lifeskim:mentions | umls-concept:C0115305 | lld:lifeskim |
| pubmed-article:9863011 | lifeskim:mentions | umls-concept:C0229671 | lld:lifeskim |
| pubmed-article:9863011 | lifeskim:mentions | umls-concept:C0278488 | lld:lifeskim |
| pubmed-article:9863011 | lifeskim:mentions | umls-concept:C0063695 | lld:lifeskim |
| pubmed-article:9863011 | lifeskim:mentions | umls-concept:C1749467 | lld:lifeskim |
| pubmed-article:9863011 | lifeskim:mentions | umls-concept:C0441889 | lld:lifeskim |
| pubmed-article:9863011 | lifeskim:mentions | umls-concept:C1707520 | lld:lifeskim |
| pubmed-article:9863011 | lifeskim:mentions | umls-concept:C2348519 | lld:lifeskim |
| pubmed-article:9863011 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:9863011 | pubmed:dateCreated | 1999-1-28 | lld:pubmed |
| pubmed-article:9863011 | pubmed:abstractText | Cellular adhesion molecules have been demonstrated to play an important role in the progression and metastasis of malignancies. We determined the serum concentrations of soluble intercellular adhesion molecule-1 (sICAM-1) and E-selectin (sE-selectin) by enzyme-linked immunosorbent assay in 49 Japanese patients with metastatic breast cancer. Significantly high concentrations of sICAM-1 and sE-selectin were found in the patients with liver and/or bone metastases (both P<0.05). The mean serum sICAM-1 levels were significantly higher in patients with two or more metastatic sites compared to those with one metastatic site (P=0.001). A significant correlation was found between serum sICAM-1 (P=0.0001) and sE-selectin (P<0.0001) and the interleukin (IL)-6 levels. The patients who did not respond to chemo/ endocrine therapy showed significantly higher sICAM-1 and sE-selectin levels compared with those who responded to therapy (P=0.0004, P=0.02, respectively). Moreover, high sICAM-1 levels predicted a significantly poorer overall survival in both univariate and multivariate analyses. Our results suggest that the shedding of sICAM-1 or sE-selectin may enhance the metastatic process by escaping from host immune surveillance. The serum sICAM-1 level may help to predict the patient response to chemo/endocrine therapy and may be of prognostic significance in metastatic breast cancer patients. | lld:pubmed |
| pubmed-article:9863011 | pubmed:language | eng | lld:pubmed |
| pubmed-article:9863011 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9863011 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:9863011 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9863011 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9863011 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9863011 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:9863011 | pubmed:month | Jan | lld:pubmed |
| pubmed-article:9863011 | pubmed:issn | 1019-6439 | lld:pubmed |
| pubmed-article:9863011 | pubmed:author | pubmed-author:AdachiII | lld:pubmed |
| pubmed-article:9863011 | pubmed:author | pubmed-author:ZhangG JGJ | lld:pubmed |
| pubmed-article:9863011 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:9863011 | pubmed:volume | 14 | lld:pubmed |
| pubmed-article:9863011 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:9863011 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:9863011 | pubmed:pagination | 71-7 | lld:pubmed |
| pubmed-article:9863011 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:9863011 | pubmed:meshHeading | pubmed-meshheading:9863011-... | lld:pubmed |
| pubmed-article:9863011 | pubmed:meshHeading | pubmed-meshheading:9863011-... | lld:pubmed |
| pubmed-article:9863011 | pubmed:meshHeading | pubmed-meshheading:9863011-... | lld:pubmed |
| pubmed-article:9863011 | pubmed:meshHeading | pubmed-meshheading:9863011-... | lld:pubmed |
| pubmed-article:9863011 | pubmed:meshHeading | pubmed-meshheading:9863011-... | lld:pubmed |
| pubmed-article:9863011 | pubmed:meshHeading | pubmed-meshheading:9863011-... | lld:pubmed |
| pubmed-article:9863011 | pubmed:meshHeading | pubmed-meshheading:9863011-... | lld:pubmed |
| pubmed-article:9863011 | pubmed:meshHeading | pubmed-meshheading:9863011-... | lld:pubmed |
| pubmed-article:9863011 | pubmed:meshHeading | pubmed-meshheading:9863011-... | lld:pubmed |
| pubmed-article:9863011 | pubmed:meshHeading | pubmed-meshheading:9863011-... | lld:pubmed |
| pubmed-article:9863011 | pubmed:meshHeading | pubmed-meshheading:9863011-... | lld:pubmed |
| pubmed-article:9863011 | pubmed:meshHeading | pubmed-meshheading:9863011-... | lld:pubmed |
| pubmed-article:9863011 | pubmed:year | 1999 | lld:pubmed |
| pubmed-article:9863011 | pubmed:articleTitle | Serum levels of soluble intercellular adhesion molecule-1 and E-selectin in metastatic breast carcinoma: correlations with clinicopathological features and prognosis. | lld:pubmed |
| pubmed-article:9863011 | pubmed:affiliation | Department of Medical Oncology, National Cancer Center Hospital, Chuo-ku, Tokyo 104, Japan. | lld:pubmed |
| pubmed-article:9863011 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:9863011 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9863011 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9863011 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9863011 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9863011 | lld:pubmed |
